🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06435260
Recruiting Phase 2

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

NCT06435260 · tracked via the Priya Life Science China tracker
Sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Started
2024-08-01
Last updated
2026-07-06

Condition(s) studied

Pancreatic Cancer

Investigational drug(s) / intervention(s)

Camrelizumab+chemotherapyhypofractionated radiotherapy

Camrelizumab+chemotherapy: Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy: AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles. Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles.

hypofractionated radiotherapy: Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),

Study summary

The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age:18 to 75 years old, male or female; 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 3. Tumor was located in the pancreas; 4. Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma; 5. No distant metastasis; 6. The pancreatic tumor is located more than 1cm away from the duodenum; 7. Clinical assessment was locally advanced or critical for resectable. Locally advanced pancreatic cancer diagnostic criteria: (1) due to tumor invasion, venous occlusion or involving a wide range of superior mesenteric vein branch of jejunum, cannot safely - superior mesenteric vein reconstruction. ② (pancreatic head/uncinate process tumors) tumor contact with superior mesenteric artery or celiac artery \> 180°. Tumor contact with superior mesenteric artery or coeliac trunk artery \> 180°, tumor contact with coeliac trunk artery and invasion of abdominal aorta. Critical for resectable pancreatic cancer diagnostic criteria: (1) contact with portal vein tumor - superior mesenteric vein \> 180 °, 180 ° or less or contact combined intravenous contour irregular or venous thrombosis, but safety is complete resection and reconstruction; The tumor contacted the inferior vena cava. ② (pancreatic head/uncinate process tumors) the tumors contacting the common hepatic artery, but not involving the celiac artery or the origin of the left and right hepatic arteries, can be completely resected and safely reconstructed; Superior mesenteric artery tumor contact 180 ° or less; The tumor contacts the aberrant arteries (such as accessory right hepatic artery, alternative right hepatic artery, alternative common hepatic artery, etc.). (pancreatic body and tail tumors) tumor contact with superior mesenteric artery ≤180°; Tumor contact with celiac artery ≤180°; 7.There was no history of immune system diseases, other malignant tumors, myocarditis, coronary heart disease, other cardiovascular and cerebrovascular diseases, thyroid dysfunction, liver and kidney diseases, psychiatric diseases, infectious diseases, or systemic diseases other than those mentioned above. Participants were willing to join in this study, good adherence and written informed consent. Exclusion Criteria: 1. Patients who did not meet these inclusion criteria; 2. Poor cognitive ability, inability to answer questions, inability to fill out questionnaires, or mental disorders; 3. The investigators think inappropriate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fourth Hospital of Hebei Medical University Shijiazhuang Hebei Recruiting

More Hebei Medical University Fourth Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06435260 on ClinicalTrials.gov ↗ ← All trials in China